PALO ALTO, Calif. – November 13, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate update at Jefferies 2017 Healthcare Conference on Thursday, November 16, 2017 at 4:40 pm CET at the Waldorf Hilton London in the Westminster Room on the Entresol Level. Eiger will also host one-on-one meetings.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to translational innovation and the repurposing of well-characterized drugs acting on newly identified or novel targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
SOURCE Eiger Bio, Inc.
Investors: Ingrid Choong, PhD
Eiger BioPharmaceuticals, Inc.